AN2 Therapeutics: director Aziz Kabeer received 2,465 shares

What happened Aziz Kabeer, a director of AN2 Therapeutics, received 2,465 shares as an award/grant on Oct 12, 2026. The filing reports a price of $0.00 per share for a total value of $0.

Key details

• Transaction date: Oct 12, 2026; transaction type/code: A (award/grant).
• Price: $0.00 per share; total value reported: $0.
• Shares owned after the transaction: not stated in the filing.
• Footnote F1: shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy; all shares vest immediately.
• Footnotes F2 and F3: certain shares are held directly by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.; Adjuvant Capital GP, L.P. and Adjuvant Capital Management, L.L.C. are the related general partners; the reporting person may be deemed to share voting and dispositive power over securities held by those entities, and each disclaims beneficial ownership except to the extent of pecuniary interest.
• Filing date: Oct 13, 2026 (reporting period Oct 12, 2026).

Why it may matter The transaction was an award issued in lieu of cash compensation and vested immediately, so it was not a market purchase or sale. A filing does not show why the insider traded or why the company acted.